SFX by Ex Libris Inc.

Title:	Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors
Source:	European Journal of Clinical Pharmacology [0031-6970] Wu, Huali yr:2013

Basic

Full text

Full text available via SpringerLINK Contemporary 1997-Present

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Suzuki, K. "Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma." European Journal of Clinical Pharmacology 72.2 (2016): 153-161.
description	2.	Xi, J.. "Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors." International journal of nanomedicine 10.Supplement 1 (2015): 1201-1222.
description	3.	Bhalla, K. "Activity of the histone deacetylase inhibitors LBH589 and LAQ824 in hematologic malignancies." Haematologica reports 1.8 (2005): 84-88.
description	4.	Qian, D. "Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589." Clinical cancer research 12.2 (2006): 634-642.
description	5.	San Miguel, Jesus E. "Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma." Pharmacological research 117 (2017): 185-191.
description	6.	Krauss, M. "Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations." PLoS ONE 10.10 (2015).
description	7.	Sharma, S. "A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors." Investigational new drugs 31.4 (2013): 974-985.
description	8.	San Miguel, Xonia F. "The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance." Cancer research 66.11 (2006): 5781-5789.
description	9.	Takai, N. "M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells." Gynecologic oncology 101.1 (2006): 108-113.
description	10.	Thakker, G D D. "The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling." The Journal of biological chemistry 274.15 (1999): 10002-10007.
description	11.	Jung, M. "Rational design and development of radiation-sensitizing histone deacetylase inhibitors." Chemistry & biodiversity 2.11 (2005): 1452-1461.
description	12.	Giles, F. "A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies." Clinical cancer research 12.15 (2006): 4628-35.
description	13.	Kerjan, G. "The transmembrane semaphorin Sema6A controls cerebellar granule cell migration." Nature neuroscience 8.11 (2005): 1516-1524.
description	14.	Shang, L. "The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons." The Journal of biological chemistry 281.4: 1876-1884.
description	15.	San-Miguel, Jacob F. "A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma." British journal of haematology 178.4 (2017): 547-560.
description	16.	Vogl, Dan T. "Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma." Clinical cancer research 23.13 (2017): 3307-432.
description	17.	Dowling, M. "Multiple myeloma: managing a complex blood cancer." British journal of nursing 25.16 (2016): 18-28.
description	18.	Houel, S. "A Phosphoproteomic Comparison of B-RAFV600Eand MKK1/2 Inhibitors in Melanoma Cells." Molecular & cellular proteomics 14.6 (2015): 1599-1615.
description	19.	Slingerland, M. "A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function." Cancer chemotherapy and pharmacology 74.5 (2014): 1089-1098.
description	20.	Bolli, N. "Heterogeneity of genomic evolution and mutational profiles in multiple myeloma." Nature communications 5.1 (2014): 2997-2997.